BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells

(2013) Christian Koelsche et al.   ACTA NEUROPATHOLOGICA

BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome

(2013) Christopher W. Toon et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations

(2013) Giusy Gentilcore et al.   BMC CANCER

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

(2013) Daniela Sia et al.   GASTROENTEROLOGY

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

(2013) Jesse S. Voss et al.   HUMAN PATHOLOGY

BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer

(2013) David Capper et al.   INTERNATIONAL JOURNAL OF CANCER

Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer

(2013) Mingzhao Xing et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Brainstem Ganglioglioma Successfully Treated With Vemurafenib

(2013) Sarah Rush et al.   JOURNAL OF CLINICAL ONCOLOGY

A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?

(2013) Johanne Lade-Keller et al.   JOURNAL OF CLINICAL PATHOLOGY

Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation

(2013) Kevin B. Kim et al.   THYROID

Targeting the BRAF V600E Mutation in Multiple Myeloma

(2013) M. Andrulis et al.   Cancer Discovery

Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia

(2012) Mindaugas Andrulis et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma

(2012) Oskar Koperek et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma

(2012) Georgina V. Long et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions

(2012) Klaus J. Busam et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients

(2012) M. Ilie et al.   ANNALS OF ONCOLOGY

Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma

(2012) M Bullock et al.   ENDOCRINE-RELATED CANCER

Detection of BRAF p.V600E Mutations in Melanomas

(2012) Emeline Colomba et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1

(2012) Alexander Skorokhod et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

BRAF Inhibition in Refractory Hairy-Cell Leukemia

(2012) Sascha Dietrich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

(2011) David Capper et al.   ACTA NEUROPATHOLOGICA

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical diagnosis and staging of cholangiocarcinoma

(2011) Boris Blechacz et al.   Nature Reviews Gastroenterology & Hepatology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

Targeting BRAF for patients with melanoma

(2010) H-T Arkenau et al.   BRITISH JOURNAL OF CANCER

Genetics of Biliary Tract Cancers and Emerging Targeted Therapies

(2010) Aram F. Hezel et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE